Teduglutide Side Effects: What Studies Report

Teduglutide is a recombinant analogue of glucagon-like peptide-2 (GLP-2), a gut hormone with trophic effects on the intestinal mucosa. It is a prescription medicine, not a research-use-only compound, and it has been studied almost entirely in people with short bowel syndrome (SBS) who depend on parenteral nutrition or intravenous fluids. A 2018 safety evaluation in Expert Opinion on Drug Safety reviewed the accumulated tolerability data for teduglutide in short bowel syndrome and organised the risk discussion around the drug's growth-promoting action on intestinal tissue (PMID 29848084). A 2024 review of teduglutide in adults with short bowel syndrome-associated intestinal failure described how the drug had been used in that population and what was monitored during treatment (PMID 37294295). This page summarises what those and other published papers reported; it does not translate any of it into personal guidance.

Why the Side-Effect Picture Is Population-Specific

Almost every safety observation for teduglutide comes from patients with intestinal failure, a group that already experiences abdominal symptoms, stoma issues, central venous catheters and fluid-electrolyte instability. The 2018 safety evaluation noted that separating drug-attributable events from the underlying disease is a recurring challenge in this literature (PMID 29848084). A 2019 review of weaning from parenteral nutrition discussed GLP-2 analogue therapy as one component of strategies aimed at reducing parenteral support, a process that itself requires careful fluid and electrolyte monitoring (PMID 31668181). Readers comparing reports should note that adverse events described in intestinal-failure cohorts cannot be assumed to generalise to other populations.

Gastrointestinal and Stoma-Related Events in Adults: What Studies Report

The 2018 safety evaluation described gastrointestinal complaints and stoma-related complications among the adverse events associated with teduglutide use in short bowel syndrome, alongside injection-site reactions (PMID 29848084). Because GLP-2 signalling promotes mucosal growth, that same evaluation framed several of the observed effects — such as stomal narrowing or swelling and abdominal discomfort — as biologically plausible consequences of intestinal tissue expansion rather than unrelated background events (PMID 29848084).

The 2024 adult review reported that clinical use of teduglutide in short bowel syndrome-associated intestinal failure involved structured follow-up, including attention to gastrointestinal symptoms and to the adjustment of intravenous support as absorption changed (PMID 37294295). Researchers writing on parenteral nutrition weaning emphasised that reductions in intravenous fluid volume must be matched to measured output and hydration status, because fluid imbalance is a practical hazard during the transition (PMID 31668181).

Post-Marketing Pharmacovigilance: What Studies Report

Spontaneous-reporting databases capture events that appear after approval, across a broader and less selected population than trials enrol. A 2025 comprehensive analysis of adverse drug reactions associated with teduglutide examined post-marketing reports and discussed the safety implications of the reaction patterns that emerged (PMID 40219687). That analysis was explicitly framed as post-marketing insight rather than controlled-trial evidence, and researchers treated the signals it produced as hypotheses for further evaluation (PMID 40219687).

A separate 2025 real-world pharmacovigilance assessment looked specifically at drug-related increases in carcinoembryonic antigen (CEA) and evaluated which medicines were disproportionately represented in reports of CEA elevation (PMID 40958286). The authors of that assessment reported disproportionality findings from a spontaneous-report database, a method that measures reporting patterns rather than incidence or causation (PMID 40958286).

Limits researchers placed on these analyses

• Post-marketing databases record reports, not confirmed diagnoses, and the 2025 teduglutide analysis presented its results as post-marketing safety signals requiring interpretation in context (PMID 40219687).
• Disproportionality metrics in the CEA assessment described relative reporting frequency and did not establish that a drug caused the laboratory change (PMID 40958286).
• The 2018 safety evaluation similarly cautioned that the intestinal-failure population's baseline morbidity complicates attribution of events to the drug (PMID 29848084).

Neoplasia, Polyps and Surveillance: What Studies Report

Because GLP-2 stimulates intestinal crypt cell proliferation, the theoretical possibility of accelerating growth of pre-existing neoplastic tissue has been a recurring topic in the safety literature. The 2018 safety evaluation discussed neoplastic and polyp-related concerns as part of its assessment of teduglutide in short bowel syndrome and linked those concerns to the rationale for endoscopic surveillance during treatment (PMID 29848084). The 2024 adult review likewise described monitoring as an element of how teduglutide was managed in intestinal-failure practice (PMID 37294295). Interest in tumour-marker reporting is reflected in the 2025 pharmacovigilance assessment of drug-related CEA increase, which evaluated CEA elevation reports across drugs in a real-world database (PMID 40958286). None of these papers, within the scope summarised here, established a confirmed causal link between teduglutide and cancer.

Pediatric Reports: What Studies Report

Children with short bowel syndrome have been studied separately, and several papers reported both benefit and tolerability observations. A 2023 study in the Journal of Pediatric Gastroenterology and Nutrition evaluated the efficacy and safety of teduglutide in infants and children with short bowel syndrome dependent on parenteral support (PMID 37364133). An earlier 2020 paper described the first real-life pediatric experience with teduglutide in short bowel syndrome, reporting outcomes outside the controlled-trial setting (PMID 32804906).

Stool output has been examined directly: a 2023 report assessed the effects of teduglutide on diarrhea in pediatric patients with short bowel syndrome-associated intestinal failure (PMID 37889619). Very small children have also been studied; an open-label study reported on teduglutide in pediatric patients under 10 kg with short bowel syndrome receiving parenteral support (PMID 41454663). Duration of exposure has been documented in case form, with a case report describing long-term use of teduglutide in a pediatric patient with short bowel syndrome (PMID 40886056). Single-patient reports describe one course of events and cannot quantify how often an event occurs.

How the pediatric papers differ

Settings Beyond Short Bowel Syndrome: What Studies Report

A 2024 paper in Transplantation and Cellular Therapy described the use of teduglutide in the management of gastrointestinal graft-versus-host disease in children and young adults, extending observation of the drug beyond its established indication (PMID 38311212). Preclinical work has explored GLP-2 biology in unrelated contexts: a 2025 Nature Metabolism study reported that GLP-2 prevented antipsychotic-induced metabolic dysfunction in mice (PMID 40114026). That study was conducted in animals, and researchers did not report human safety outcomes in it (PMID 40114026).

Where Human Safety Data Are Absent

The verified literature summarised here does not include controlled human safety studies of teduglutide in healthy volunteers, in people without intestinal failure or graft-versus-host disease, or for body composition, athletic, cosmetic or general "gut health" purposes. That is an absence of evidence, stated plainly: no paper cited on this page reported adverse-event rates for such uses. Extrapolating the tolerability profile observed in short bowel syndrome cohorts — where the 2018 safety evaluation described events against a background of severe intestinal disease — to unstudied populations is not supported by the papers cited here (PMID 29848084).

How to Read This Literature

1. Distinguish study designs. Controlled pediatric evaluations reported efficacy and safety under protocol conditions (PMID 37364133), while real-life series described unselected clinical practice (PMID 32804906).
2. Treat database signals as signals. The 2025 post-marketing analysis reported adverse drug reaction patterns drawn from spontaneous reports rather than measured incidence (PMID 40219687).
3. Separate laboratory findings from diagnoses. The CEA pharmacovigilance assessment examined reports of a marker increase, not confirmed malignancy (PMID 40958286).
4. Note context of care. Reviews of parenteral nutrition weaning described intensive monitoring as inseparable from the therapy itself (PMID 31668181).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision. Readers who want background on GLP-2 biology, indications and study design can work through the PeptideU teduglutide course, which teaches the mechanism and trial landscape rather than cataloguing adverse events.

References

• Teduglutide for the treatment of short bowel syndrome - a safety evaluation (Expert Opinion on Drug Safety, 2018)
• Weaning from Parenteral Nutrition (Gastroenterology Clinics of North America, 2019)
• Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data (Journal of Pediatric Gastroenterology and Nutrition, 2020)
• Use of teduglutide in adults with short bowel syndrome-associated intestinal failure (Nutrition in Clinical Practice, 2024)
• Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support (Journal of Pediatric Gastroenterology and Nutrition, 2023)
• Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure (Journal of Pediatric Gastroenterology and Nutrition, 2023)
• Use of Teduglutide in the Management of Gastrointestinal Graft-versus-Host Disease in Children and Young Adults (Transplantation and Cellular Therapy, 2024)
• GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice (Nature Metabolism, 2025)
• Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications (Expert Opinion on Drug Safety, 2025)
• A case report on the long-term use of teduglutide in a pediatric patient with short bowel syndrome (Nutrition in Clinical Practice, 2026)
• A real-world pharmacovigilance assessment of drug-related carcinoembryonic antigen increase (Medicine, 2025)
• Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study (Pediatrics International, 2026)